Skip to content
DraconiticResearch
Search Sources API
197,787 studies31 sourcesUpdated 45 min ago
Peer-reviewedCC BYFrontiers in oncology

Efficacy of endoscopic ultrasound-guided versus surgical gastrojejunostomy for malignant gastric outlet obstruction: a systematic review and meta-analysis

  • Furui Zhong1
  • Dali Xiong2
  • Hao Zhang3
  • Guosong Luo4
4 affiliations
  1. 1Department of General Surgery, Zigong Fourth People’s Hospital , , ,
  2. 22Department of Oncology Zigong, Fourth People’s Hospital , , ,
  3. 3Department of Hepatobiliary and Pancreatic Surgery, Meishan People’s Hospital , , ,
  4. 4Department of Center for Hepatobiliary-Pancreatic- Splenic Diseases Zigong Fourth People’s Hospital , , ,
Read full textPDFDOICite

Abstract

Objective: To systematically compare the key outcomes of endoscopic ultrasound-guided gastrojejunostomy (EUS-GJ) versus surgical gastrojejunostomy (SGJ) for the palliative treatment of malignant gastric outlet obstruction (MGOO).

Methods: A systematic review and meta-analysis was conducted in accordance with the PRISMA statement. Databases including PubMed, Embase, Web of Science and Cochrane Library were comprehensively searched from inception to December 2025 for comparative studies of EUS-GJ and SGJ in treating MGOO. Meta-analysis was performed using a random-effects model, with subgroup and sensitivity analyses.

Results: Eight studies involving 760 patients were included. Pooled analysis showed no significant differences between EUS-GJ and SGJ in technical success (RR = 0.98, P = 0.08), clinical success (RR = 1.08, P = 0.07), obstruction recurrence (RR = 0.48, P = 0.05), or re-intervention rates (RR = 1.48, P = 0.61). However, the EUS-GJ group demonstrated significant advantages, including a shorter length of hospital stay (MD= -3.57 days, P<0.001), a quicker time to first oral intake (MD= -2.88 days, P<0.001), a shorter time to resume chemotherapy (MD= -16.05 days, P<0.001), and a lower overall adverse events rate (RR = 0.44, P = 0.008).

Conclusion: For the palliative management of MGOO, EUS-GJ showed no statistically significant difference in primary efficacy endpoints compared with SGJ, but it might be associated with faster recovery and improved safety.

Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD420261308316.

Related

  1. Endoscopic Sphincterotomy Prior to Biliary Stenting for Malignant Biliary Obstruction: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
    Sofia Coelho Meine, Gabriel de Oliveira Amaral, Mateus Rech Tedesco +3
    Journal of Gastroenterology and HepatologyPeer-reviewedCC BY 4.0Full text3 citedGeneral medicinePMC
  2. Prophylactic endoscopic transpapillary gallbladder stenting at fully covered self-expandable metal stent placement to prevent cholecystitis in malignant distal biliary obstruction: A multicenter prospective single-arm study protocol (PROTECT study)
    Takayuki Oda, Yusuke Kurita, Masato Suzuki +9
    PLOS OnePeer-reviewedCC BYFull textGeneral biologyEpidemiology & public healthPLOSEurope PMCPMC
  3. EUS-Guided Choledochoduodenostomy with Lumen-Apposing Metal Stent versus ERCP with Self-Expandable Metal Stent as Primary Biliary Drainage for Malignant Distal Biliary Obstruction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    L. Ying, K. He, L. Jin +3
    medRxivPreprintAll rights reservedFull textSurgery & anaesthesiamedRxiv
  4. Malignant Large Bowel Obstruction Masquerading as Benign Inflammatory Disease in a Young Male: A Cautionary Tale of Diagnostic Delay
    Varsha G Baker, William G Baker, Sindhu Para +3
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Feasibility and Safety of a Novel Pig‐tail Inside Stent for Unresectable Malignant Hilar Biliary Obstruction: A Single‐center Case Series (With Video)
    Motoyasu Kan, Daiki Takahashi, Sodai Uchida +13
    DEN openPeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{zhong2026efficacy,
  title = {{Efficacy of endoscopic ultrasound-guided versus surgical gastrojejunostomy for malignant gastric outlet obstruction: a systematic review and meta-analysis}},
  author = {Furui Zhong and Dali Xiong and Hao Zhang and Guosong Luo},
  journal = {Frontiers in oncology},
  year = {2026},
  month = oct,
  doi = {10.3389/fonc.2026.1943827},
  url = {https://europepmc.org/article/PMC/PMC13690527},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Efficacy of endoscopic ultrasound-guided versus surgical gastrojejunostomy for malignant gastric outlet obstruction: a systematic review and meta-analysis
AU  - Furui Zhong
AU  - Dali Xiong
AU  - Hao Zhang
AU  - Guosong Luo
PY  - 2026
DA  - 2026/10/09
JO  - Frontiers in oncology
DO  - 10.3389/fonc.2026.1943827
UR  - https://europepmc.org/article/PMC/PMC13690527
AB  - Objective: To systematically compare the key outcomes of endoscopic ultrasound-guided gastrojejunostomy (EUS-GJ) versus surgical gastrojejunostomy (SGJ) for the palliative treatment of malignant gastric outlet obstruction (MGOO).  Methods: A systematic review and meta-analysis was conducted in accordance with the PRISMA statement. Databases including PubMed, Embase, Web of Science and Cochrane Library were comprehensively searched from inception to December 2025 for comparative studies of EUS-GJ and SGJ in treating MGOO. Meta-analysis was performed using a random-effects model, with subgroup and sensitivity analyses.  Results: Eight studies involving 760 patients were included. Pooled analysis showed no significant differences between EUS-GJ and SGJ in technical success (RR = 0.98, P = 0.08), clinical success (RR = 1.08, P = 0.07), obstruction recurrence (RR = 0.48, P = 0.05), or re-intervention rates (RR = 1.48, P = 0.61). However, the EUS-GJ group demonstrated significant advantages, including a shorter length of hospital stay (MD= -3.57 days, P<0.001), a quicker time to first oral intake (MD= -2.88 days, P<0.001), a shorter time to resume chemotherapy (MD= -16.05 days, P<0.001), and a lower overall adverse events rate (RR = 0.44, P = 0.008).  Conclusion: For the palliative management of MGOO, EUS-GJ showed no statistically significant difference in primary efficacy endpoints compared with SGJ, but it might be associated with faster recovery and improved safety.  Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD420261308316.
SN  - 2234-943X
ER  -